Log In
Print
BCIQ
Print
Print this Print this
 

RetinoStat

  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionLentiVector-based gene therapy designed to deliver 2 anti-angiogenic genes, endostatin and angiostatin, directly to the retina
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Lentivirus
Latest Stage of DevelopmentPhase I
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat vision loss; Treat wet age-related macular degeneration (AMD)
Regulatory Designation

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today